Multiplicity of EGFR and KRAS mutations in Non-small Cell Lung Cancer (NSCLC) patients treated with tyrosine kinase inhibitors

Anticancer Research

Volumn 30, Issue 5, 2010, Pages 1667-1671

  Lucie, Benesova ^a   Marek, Minarik ^a   Dana, Jancarikova ^b   Barbora, Belsanova ^a   Milos, Pesek ^b  

^a Laboratory for Molecular Genetics and Oncology   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Clonality; EGFR; KRAS; Multiplicity; Mutation; NSCLC

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; K RAS PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ALLERGIC REACTION; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; GASTROINTESTINAL TOXICITY; GENE DELETION; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; TREATMENT RESPONSE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, GENETIC; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77954580523     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sanchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ and Taron M: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967, 2009.
2. Sequist LV, Bell DW, Lynch TJ and Haber DA: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small cell lung cancer. J Clin Oncol 25: 587-595, 2007.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
5. Li T and Perez-Soler R: Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4: 107-119, 2009.
6. Riely GJ and Ladanyi M: KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn 10: 493-495, 2008.
7. Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, Lipkowitz S, Husain AN, Salgia R and Ma PC: Gefitinib response of erlotinib-refractory lung cancer involving meninges role of EGFR mutation. Nat Clin Pract Oncol 3: 50-57, 2006.
8. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, Miller VA and Ladanyi M: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14: 5731-5734, 2008.
9. Pesek M, Benesova L, Belsanova B, Mukensnabl P, Bruha F and Minarik M: Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Anticancer Res 29: 2767-2773, 2009.
10. Girard N, Deshpande C, Azzoli CG, Rusch VW, Travis WD, Ladanyi M and Pao W: Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest 137: 46-52, 2010.
11. Kamath S and Buolamwini JK: Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev 26: 569-594, 2006. (Pubitemid 44230413)
12. Greenman C, Wooster R, Futreal PA, Stratton MR and Easton DF: Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics 173: 2187-2198, 2006. (Pubitemid 44285695)
13. Zhu CQ, da Cunha SG, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA and Tsao MS: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26: 4268-4275, 2008.
14. Pallis AG, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, Koutsopoulos A, Tripaki M, Stathopoulos E, Mavroudis D and Georgoulias V: 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer 97: 1560-1566, 2007.
15. Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH and Bang YJ: Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 12: 2538-2544, 2006.
16. Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E and Taron M: Treatment of non-small cell lung cancer and pharmacogenomics: where we are and where we are going. Curr Opin Oncol 18: 135-143, 2006. (Pubitemid 43740433)
17. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M and Miller VA: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839-844, 2006.
18. Jiang SX, Yamashita K, Yamamoto M, Piao CJ, Umezawa A, Saegusa M, Yoshida T, Katagiri M, Masuda N, Hayakawa K and Okayasu I: EGFR genetic heterogeneity of non-small cell lung cancers contributing to acquired gefitinib resistance. Int J Cancer 123: 2480-2486, 2008.